Palatin Technologies Inc banner

Palatin Technologies Inc
LSE:0KF3

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
LSE:0KF3
Watchlist
Price: 27.71 USD 110.72% Market Closed
Market Cap: $761.2B

Multiples-Based Value

The Multiples-Based Value of one 0KF3 stock under the Base Case scenario is hidden USD. Compared to the current market price of 27.71 USD, Palatin Technologies Inc is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0KF3 Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

0KF3 Competitors Multiples
Palatin Technologies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Palatin Technologies Inc
LSE:0KF3
34m USD 4.4 -4.1 -2.6 -2.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
374.1B USD 6.1 89.4 14.8 20.5
US
Amgen Inc
NASDAQ:AMGN
183.3B USD 5.1 24.4 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
172.3B USD 6 20.7 12.9 15.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.7B USD 9.4 28.5 21.4 22.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.4B USD 5.7 18.2 13.7 15.6
NL
argenx SE
XBRU:ARGX
41B EUR 11.7 37.5 40.8 41.7
AU
CSL Ltd
ASX:CSL
67.6B AUD 3 33.6 11.3 14.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Palatin Technologies Inc
LSE:0KF3
Average P/S: 3 063 003.2
4.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
NL
argenx SE
XBRU:ARGX
11.7
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Palatin Technologies Inc
LSE:0KF3
Average P/E: 36
Negative Multiple: -4.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.4
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.4
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.7
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.5
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
NL
argenx SE
XBRU:ARGX
37.5
32%
1.2
AU
CSL Ltd
ASX:CSL
33.6
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Palatin Technologies Inc
LSE:0KF3
Average EV/EBITDA: 18.4
Negative Multiple: -2.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
18%
0.8
NL
argenx SE
XBRU:ARGX
40.8
50%
0.8
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Palatin Technologies Inc
LSE:0KF3
Average EV/EBIT: 20.6
Negative Multiple: -2.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.5
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.9
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
23%
0.7
NL
argenx SE
XBRU:ARGX
41.7
51%
0.8
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett